19,744 results match your criteria urothelial


WNT7B represses epithelial-mesenchymal transition and stem-like properties in bladder urothelial carcinoma.

Biochim Biophys Acta Mol Basis Dis 2021 Sep 22:166271. Epub 2021 Sep 22.

Department of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, China. Electronic address:

Background: Recurrence and metastasis are the major problems of bladder urothelial carcinoma, which mainly attribute to tumor cell stemness, epithelial-mesenchymal transition (EMT) and chemoresistance.

Methods: TCGA database was interrogated for gene mRNA expression in bladder urothelial carcinoma samples. CCLE database was interrogated for gene mRNA expression in bladder cancer cell lines. Read More

View Article and Full-Text PDF
September 2021

COVID-19 pandemic impact on uro-oncological disease outcomes at an Italian tertiary referral center.

World J Urol 2021 Sep 25. Epub 2021 Sep 25.

Division of Urology, Department of Surgical Sciences - Urology, Città della Salute e della Scienza di Torino - Molinette Hospital, University of Turin, Turin, Italy.

Purpose: To assess differences in referral and pathologic outcomes for uro-oncology cases prior to and during the COVID pandemic, comparing clinical and pathological data of cancer surgeries performed at an academic referral center between 2019 and 2020.

Methods: We collected data of 880 prostate biopsies, 393 robot-assisted radical prostatectomies (RARP) for prostate cancer (PCa), 767 trans-urethral resections of bladder tumor (TURB) and 134 radical cystectomies (RC) for bladder cancer (BCa), 29 radical nephro-ureterectomies (RNU) for upper tract urothelial carcinoma, 130 partial nephrectomies (PN) and 12 radical nephrectomies (RN) for renal cancer, and 41 orchifunicolectomies for testicular cancer. Data of patients treated in 2019 (before COVID-19 pandemic) were compared to patients treated in 2020 (during pandemic). Read More

View Article and Full-Text PDF
September 2021

Tumor distribution affects bladder recurrence but not survival outcome of multifocal upper tract urothelial carcinoma treated with radical nephroureterectomy.

Sci Rep 2021 Sep 24;11(1):19059. Epub 2021 Sep 24.

Department of Urology, Kaohsiung Medical University Hospital, No. 100, Shih-Chuan 1st Road, Sanmin Dist., Kaohsiung, 80708, Taiwan.

Tumor multifocality and location are prognostic factors for upper tract urothelial carcinoma (UTUC). However, confounding effects can appear when these two factors are analyzed together. Therefore, we aimed to investigate the impact of tumor distribution on the outcomes of multifocal UTUC after radical nephroureterectomy. Read More

View Article and Full-Text PDF
September 2021

Current Evidence and Future Perspectives in the Management of Nonmetastatic Upper Tract Urothelial Carcinoma.

Eur Urol Oncol 2021 Sep 21. Epub 2021 Sep 21.

Urology, GRC n°5, Predictive Onco-Urology, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne University, Paris, France. Electronic address:

This case-based discussion describes the management of a 66-yr-old man who presented to the emergency department with gross hematuria. His urine cytology was benign, and computed tomography (CT) with nephrographic phase revealed a 2.5 cm filling defect within the left renal pelvis and luminal narrowing in the right proximal ureter with hydronephrosis. Read More

View Article and Full-Text PDF
September 2021

Utility of D2-40, Cytokeratin 5/6, and High-Molecular-weight Cytokeratin (Clone 34βE12) in Distinguishing Intraductal Spread of Urothelial Carcinoma From Prostatic Stromal Invasion.

Am J Surg Pathol 2021 Sep 23. Epub 2021 Sep 23.

Departments of Pathology and Laboratory Medicine Urology Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL.

Intraductal spread of urothelial carcinoma (UC) is not an uncommon finding in bladder cancer that requires appropriate clinical management. The presence of prostatic stromal invasion in non-muscle-invasive bladder cancer upstages the disease, necessitating cisplatin-based neoadjuvant chemotherapy and subsequent cystroprostatectomy. However, the identification of prostatic stromal invasion can be challenging, especially in biopsy and transurethral resection specimens. Read More

View Article and Full-Text PDF
September 2021

Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications.

Virchows Arch 2021 Sep 24. Epub 2021 Sep 24.

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.

Cytokeratins (CKs) 5 and 6 are functionally unrelated but often analyzed together using bispecific antibodies in diagnostic immunohistochemistry. To better understand the diagnostic utility of CK5 or CK6 alone, tissue microarrays with > 15,000 samples from 120 different tumor types as well as 608 samples of 76 different normal tissues were analyzed by immunohistochemistry. In normal tissues, both CKs occurred in the squamous epithelium; CK5 dominated in basal and CK6 in suprabasal layers. Read More

View Article and Full-Text PDF
September 2021

Dysfunction of miR-802 in tumors.

J Clin Lab Anal 2021 Sep 24:e23989. Epub 2021 Sep 24.

Medical Genetics Center, Ningbo University School of Medicine, Ningbo, China.

Recent studies have shown that miR-802 is abnormally expressed in many tumors. miR-802 is expressed at low levels in tissues and cells of gastric cancer, colorectal cancer, breast cancer, cervical cancer, epithelial ovarian cancer, tongue squamous cell carcinoma, oral squamous cell carcinoma, esophageal squamous cell carcinoma, laryngeal squamous cell carcinoma, and melanoma. In contrast, miR-802 is overexpressed in hepatocellular carcinoma, bladder urothelial cancer, osteosarcoma, and cholesteatoma tissue cells. Read More

View Article and Full-Text PDF
September 2021

Conservative Treatment for Upper Urinary Tract Urothelial Carcinoma.

Eur Urol Open Sci 2021 Oct 13;32:38-39. Epub 2021 Sep 13.

GRC Urolithiasis no. 20, Sorbonne University, Tenon Hospital, Paris, France.

View Article and Full-Text PDF
October 2021

RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics.

J Clin Invest 2021 Sep 23. Epub 2021 Sep 23.

Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America.

Bladder cancer is a genetically heterogeneous disease and novel therapeutic strategies are needed to expand treatment options and improve clinical outcomes. Here we identified a unique subset of urothelial tumors with focal amplification of the RAF1 (CRAF) kinase gene. RAF1-amplified tumors had activation of the RAF/MEK/ERK signaling pathway and exhibited a luminal gene expression pattern. Read More

View Article and Full-Text PDF
September 2021

PLAUR as a Potential Biomarker Associated with Immune Infiltration in Bladder Urothelial Carcinoma.

J Inflamm Res 2021 15;14:4629-4641. Epub 2021 Sep 15.

Department of Obstetrics and Gynecology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, 116011, People's Republic of China.

Background: Bladder urothelial carcinoma (BLCA) is one of the most lethal and aggressive malignancies of genitourinary system that affects human health. The urokinase plasminogen activator receptor (PLAUR) plays essential roles in tumorigenesis and immune modulation, and its aberrant expression is closely correlated with cancer progression. However, whether PLAUR has the potential to be one promising biomarker or immunotherapy target for BLCA is unknown. Read More

View Article and Full-Text PDF
September 2021

CD8 T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer.

Oncogene 2021 Sep 22. Epub 2021 Sep 22.

Department of Oncology, Third Xiangya Hospital, Central South University, 283 Tongzipo Road, Changsha, 410013, China.

Immune-checkpoint blockade (ICB) has been routinely implemented to treat bladder cancer; however, most patients have little or no clinical benefit. In this study, 348 pretreated metastatic urothelial cancer samples from the IMvigor210 cohort were used to identify important genes significantly associated with CD8+ T effector and immune checkpoint signatures. The immune checkpoint inhibitor score (IMS) scoring system was constructed to predict the immunotherapy responsiveness. Read More

View Article and Full-Text PDF
September 2021

Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study.

Cancer Discov 2021 Sep 22. Epub 2021 Sep 22.

Internal Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School.

Futibatinib, a highly selective, irreversible FGFR1-4 inhibitor, was evaluated in a large multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid tumors. Futibatinib demonstrated an objective response rate (ORR) of 13.7%, with responses in a broad spectrum of tumors (cholangiocarcinoma and gastric, urothelial, central nervous system, head and neck, and breast cancer) bearing both known and previously uncharacterized FGFR1-3 aberrations. Read More

View Article and Full-Text PDF
September 2021

Unusual endophytic non-enhancing tumour in the renal pelvis: a diagnostic dilemma.

BMJ Case Rep 2021 Sep 22;14(9). Epub 2021 Sep 22.

Histopathology, PGIMER, Chandigarh, Chandigarh, India.

Renal cell cancer (RCC) is incidentally detected on imaging in 50%-60% of cases. Among the RCCs, clear cell variant is most common and classically seen as heterogenous enhancing lesion on CT imaging. Hypoenhancing mass presents a diagnostic dilemma with differential diagnosis being urothelial carcinoma, fat poor angiomyolipoma, oncocytoma or rarer variants of RCC. Read More

View Article and Full-Text PDF
September 2021

HA-coated collagen nanofibers for urethral regeneration via in situ polarization of M2 macrophages.

J Nanobiotechnology 2021 Sep 22;19(1):283. Epub 2021 Sep 22.

Department of Pediatric Surgery, Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, Guangdong, China.

In situ tissue engineering utilizes the regenerative potential of the human body to control cell function for tissue regeneration and has shown considerable prospect in urology. However, many problems are still to be understood, especially the interactions between scaffolds and host macrophages at the wound site and how these interactions direct tissue integration and regeneration. This study was designed to evaluate the efficacy of hyaluronic acid (HA) functionalized collagen nanofibers in modulating the pro-healing phenotype expression of macrophages for urethral regeneration. Read More

View Article and Full-Text PDF
September 2021

Prediagnostic Serum 25-Hydroxyvitamin D and Mortality Among Bladder Cancer Patients in the Janus Serum Bank Cohort.

Clin Epidemiol 2021 14;13:801-811. Epub 2021 Sep 14.

Department of Research, Cancer Registry of Norway, Oslo, Norway.

Purpose: Circulating 25-hydroxyvitamin D (25(OH)D) is inversely associated with overall cancer mortality and selected cancers, while for urothelial bladder cancer (BC) this relationship is unclear. We aimed to examine the association between 25(OH)D and BC mortality.

Materials And Methods: We used prediagnostic serum from 378 BC cases within the population-based Janus Cohort. Read More

View Article and Full-Text PDF
September 2021

Development and Validation of a Risk-Adapted Scoring Model for Metachronous Upper Tract Urothelial Carcinoma Following Radical Cystectomy.

J Urol 2021 Sep 22:101097JU0000000000002211. Epub 2021 Sep 22.

Department of Urology, Mayo Clinic, Rochester, Minnesota.

Introduction: The incidence and risk factors for metachronous upper tract urothelial carcinoma (UTUC) following radical cystectomy (RC) remain incompletely defined, which has limited the ability to individualize postoperative surveillance.

Methods: A retrospective review of two institutional registries was performed to identify patients undergoing RC for urothelial carcinoma. Multivariable Cox proportional hazard models for metachronous post-RC UTUC were developed in one institutional dataset and validated in the second institutional dataset. Read More

View Article and Full-Text PDF
September 2021

Role of GATA3 in tumor diagnosis: A review.

Pathol Res Pract 2021 Sep 13;226:153611. Epub 2021 Sep 13.

Department of Pathology, Dr. Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran; Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:

GATA binding protein 3 (GATA3) belongs to a family of transcription factors comprising six members. These proteins identify G-A-T-A containing sequences in the target gene and bind to DNA target via two zinc-finger domains. The aim of this study was to evaluate the role of GATA3 in the diagnosis of tumors and its value as a prognostic marker. Read More

View Article and Full-Text PDF
September 2021

Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab.

Int J Urol 2021 Sep 20. Epub 2021 Sep 20.

Department of Urology, University of Toyama, Toyama, Japan.

Objectives: To investigate the impact of the number of cycles and objective response to chemotherapy on overall survival in patients with metastatic urothelial carcinoma treated with pembrolizumab.

Methods: This multicenter, retrospective study included 755 patients from 59 institutions with advanced, chemoresistant urothelial carcinoma who received pembrolizumab. The associations of the overall survival with the number of cycles and best objective response were investigated using Cox multiple regression analysis. Read More

View Article and Full-Text PDF
September 2021

Mechanistic study of lncRNA UCA1 promoting growth and cisplatin resistance in lung adenocarcinoma.

Cancer Cell Int 2021 Sep 20;21(1):505. Epub 2021 Sep 20.

Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.

Aim: This study aimed to explore the mechanism of LncRNA urothelial carcinoma-associated 1 (UCA1) promoting cisplatin resistance in lung adenocarcinoma (LUAD).

Method: The UCA1 expression level in LUAD cell lines was detected by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). We overexpressed UCA1 in A549 cells and downregulated UCA1 in A549/DDP cells by the lentivirus‑mediated technique. Read More

View Article and Full-Text PDF
September 2021

Conservative Treatment of Upper Urinary Tract Urothelial Carcinoma: Referee.

Eur Urol Open Sci 2021 Oct 9;32:40-42. Epub 2021 Sep 9.

GRC 5 Predictive Onco-Urology, Sorbonne University, APHP, Pitié-Salpêtrière Hôpital, Paris, France.

View Article and Full-Text PDF
October 2021

Immune escape mechanisms and immunotherapy of urothelial bladder cancer.

J Clin Transl Res 2021 Aug 30;7(4):485-500. Epub 2021 Jul 30.

Department of Biomedical Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.

Background And Aim: Urothelial bladder cancer (UBC) is a common malignant tumor of the urogenital system with a high rate of recurrence. Due to the sophisticated and largely unexplored mechanisms of tumorigenesis of UBC, the classical therapeutic approaches including transurethral resection and radical cystectomy combined with chemotherapy have remained unchanged for decades. However, with increasingly in-depth understanding of the microenvironment and the composition of tumor-infiltrating lymphocytes of UBC, novel immunotherapeutic strategies have been developed. Read More

View Article and Full-Text PDF

Paraganglioma of Urinary Bladder: An Uncommon Entity in Uropathology.

Cureus 2021 Aug 17;13(8):e17265. Epub 2021 Aug 17.

Urology, Royal Hospital, Muscat, OMN.

Paraganglioma of the urinary bladder is a rare neoplasm. It may be functional, secreting catecholamines, or nonfunctional. Clinically and histopathologically, it has the potential to be misdiagnosed as a more common urothelial carcinoma, especially in nonfunctional cases. Read More

View Article and Full-Text PDF

Mismatch repair deficiency in canine neoplasms.

Vet Pathol 2021 Sep 19:3009858211022704. Epub 2021 Sep 19.

Yamaguchi University, Yamaguchi, Japan.

The DNA mismatch repair (MMR) system preserves genomic stability by identifying and repairing mismatched nucleotides in the DNA replication process. The dysfunction of the MMR system, also known as mismatch repair deficiency (dMMR), is implicated as a predictive biomarker for the efficacy of immune checkpoint blockade therapy regardless of the tumor type in humans. This study aimed to evaluate the immunolabeling of MMR proteins in canine tumors and to identify the types of tumors having dMMR. Read More

View Article and Full-Text PDF
September 2021

Endoscopic Management of Low-Grade Upper Tract Urothelial Carcinoma: Characterizing the Long-term Burden of Care in Comparison to Radical Nephroureterectomy.

Urology 2021 Sep 15. Epub 2021 Sep 15.

Department of Urology, Rabin Medical Center, Petah Tikva, Israel, affiliated with the Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel. Electronic address:

Objectives: To compare procedure burden, oncologic, surgical and renal-function outcomes between patients with low-grade upper urothelial cancer (UTUC) who were referred for either radical management (RM) or kidney-sparing endoscopic management (EM).

Patients And Methods: We retrospectively reviewed data of all patients treated for UTUC at our tertiary medical center between 2000 and 2018 and selected patients diagnosed with unilateral low-grade UTUC.

Results: 24 patients were treated with EM and 37 with RM. Read More

View Article and Full-Text PDF
September 2021

Overall Survival of Patients Receiving Cisplatin or Carboplatin for Primary Metastatic Urothelial Carcinoma of the Bladder: A Contemporary Dutch Nationwide Cohort Study.

Eur Urol Focus 2021 Sep 14. Epub 2021 Sep 14.

Department of Research and Development, The Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands; Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

Background: Cisplatin is preferred to carboplatin when treating metastatic urothelial carcinoma of the bladder (mUCB), despite its greater toxicity. Randomised studies underpinning this have been performed in noncontemporary populations with limitations in sample sizes and analyses, affecting their validity in current clinical practice.

Objective: To estimate overall survival (OS) and assess the benefit of cisplatin-based regimens over carboplatin-based regimens in a contemporary cohort of patients with mUCB. Read More

View Article and Full-Text PDF
September 2021

Reply to G. Francolini et al.

J Clin Oncol 2021 Sep 17:JCO2101977. Epub 2021 Sep 17.

Anthony V. D'Amico, MD, PhD, Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA; Wanling Xie, MS, Department of Data Sciences, Dana Farber Cancer Institute, Boston, MA; and Philip W. Kantoff, MD, Department of Medicine, Memorial Sloan Kettering Cancer Institute, New York, NY.

View Article and Full-Text PDF
September 2021

Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.

Front Immunol 2021 31;12:721030. Epub 2021 Aug 31.

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

Background: Poly (ADP-ribose) polymerases-1 (PARP1) alterations are associated with PARP1 inhibitor resistance, regulating the function of Treg cells and PDL1 expression in tumor cells, and high PARP1 expression is significantly associated with aggressive behavior and chemotherapeutic resistance in several tumors. However, a comprehensive analysis of the predictive values of PARP1 alteration for immune checkpoint inhibitor (ICI) effectiveness in tumors remains unclear, and the associations between its expression and immunotherapy signatures also needs to be explored further.

Methods: We performed some analyses with the cBioPortal online database (https://www. Read More

View Article and Full-Text PDF